---
title: "Nash Maintains Buy on Viking Therapeutics, Keeps $107 Price Target Unchanged Amid Strong Cash Runway and Expanded VK2735 Study"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285077523.md"
description: "Analyst Edward Nash from Canaccord Genuity has maintained a Buy rating on Viking Therapeutics with a price target of $107. Despite a larger-than-expected quarterly loss due to high R&D spending, the company has over $600M in cash, ensuring operations are funded into 2028. Nash highlights the expansion of the VK2735 study as a key value driver. BTIG also reiterated a Buy rating with a $125 price target."
datetime: "2026-05-04T13:05:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285077523.md)
  - [en](https://longbridge.com/en/news/285077523.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285077523.md)
---

# Nash Maintains Buy on Viking Therapeutics, Keeps $107 Price Target Unchanged Amid Strong Cash Runway and Expanded VK2735 Study

Viking Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst on May 1. Analyst Edward Nash from Canaccord Genuity maintained a Buy rating on the stock and has a $107.00 price target.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Edward Nash has given his Buy rating due to a combination of factors, including Viking Therapeutics’ solid capital position and advancing clinical programs. Despite a larger‑than‑expected quarterly loss driven by elevated R&D spending, the company still holds over $600M in cash, and management projects this cash runway will comfortably fund operations into 2028, even as investment in development remains high near term.

Nash also highlights the strategic expansion of the Phase I maintenance-dosing study of VK2735, which has been broadened from four to eight treatment arms to generate more robust efficacy and safety data. He views this trial modification as an important value driver for the pipeline and, coupled with the company’s strengthened financial visibility, supports maintaining a Buy rating and an unchanged $107 price target for VKTX shares.

In another report released on May 1, BTIG also reiterated a Buy rating on the stock with a $125.00 price target.

### Related Stocks

- [VKTX.US](https://longbridge.com/en/quote/VKTX.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)

## Related News & Research

- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md)
- [Wave Life Sciences posts positive RestorAATion-2 data; WVE-006 restores M-AAT, cuts Z-AAT, supports monthly dosing](https://longbridge.com/en/news/286818220.md)